BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32476768)

  • 1. Diagnostic Value of Risk of Malignancy Algorithm (ROMA) in Adnexal Masses.
    Kumar V; Rajan S; Gupta S; Akhtar N; Sharma S; Sinha P; Misra S; Chaturvedi A
    J Obstet Gynaecol India; 2020 Jun; 70(3):214-219. PubMed ID: 32476768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
    Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
    J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
    Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.
    Al Musalhi K; Al Kindi M; Al Aisary F; Ramadhan F; Al Rawahi T; Al Hatali K; Mula-Abed WA
    Oman Med J; 2016 Sep; 31(5):336-44. PubMed ID: 27602187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
    J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses.
    Farzaneh F; Honarvar Z; Yaraghi M; Yaseri M; Arab M; Hosseini M; Ashrafgangoi T
    Iran Red Crescent Med J; 2014 Jun; 16(6):e17185. PubMed ID: 25068046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
    Yang Y; Ju H; Huang Y
    Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
    Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
    Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions.
    Czekierdowski A; Stachowicz N; Smolen A; Łoziński T; Guzik P; Kluz T
    Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
    Janas L; Głowacka E; Wilczyński JR; Malinowski A; Nowak M
    Ginekol Pol; 2015 Mar; 86(3):193-7. PubMed ID: 25920309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.
    Choi HJ; Lee YY; Sohn I; Kim YM; Kim JW; Kang S; Kim BG
    Curr Probl Cancer; 2020 Apr; 44(2):100508. PubMed ID: 31708114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.
    Carreras-Dieguez N; Glickman A; Munmany M; Casanovas G; Agustí N; Díaz-Feijoo B; Saco A; Sánchez B; Gaba L; Angeles MA; Pahisa J; Fernández-Galán E; Torné A; Fusté P
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.
    Chacón E; Dasí J; Caballero C; Alcázar JL
    Gynecol Obstet Invest; 2019; 84(6):591-598. PubMed ID: 31311023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
    Abdalla N; Piorkowski R; Bachanek M; Stanirowski P; Cendrowski K; Sawicki W
    Dis Markers; 2018; 2018():5289804. PubMed ID: 29849823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.